<DOC>
	<DOCNO>NCT00219258</DOCNO>
	<brief_summary>Zoledronic acid medication slow breakdown bone . This study ass efficacy safety zoledronic acid Chinese patient multiple myeloma solid tumor bone metastasis .</brief_summary>
	<brief_title>Efficacy Safety Zoledronic Acid Patients With Bone Metastases Any Solid Tumors Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Criteria Cancer patient ( multiple myeloma solid tumor ) confirm evidence bone lesion Significant bone pain Exclusion Criteria Poor renal function Use investigational drug within 30 day visit 2 Dental surgery jaw within 6 week screen , plan 4 week study Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>